Abstract

Cardioversion in atrial fibrillation (AF) is associated with an increased risk of thromboembolism. Current recommendations advise therapy with the anticoagulant warfarin both before and after cardioversion. A new post hoc analysis of data from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial shows that the novel anticoagulant dabigatran is a safe alternative to warfarin in patients with AF who undergo cardioversion.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call